As Sannova expands into new areas, small molecule bioanalysis has been at the core of Sannova’s success since its founding in 2006. Beginning with a 4,000 square foot laboratory with a capacity of a few thousand samples per month, Sannova has now grown to a 21,000 square foot lab with a capacity of 360,000 samples per year.
The company has always welcomed dealing with challenging assays. Sannova was one of the first commercial laboratories to develop and validate methods for both Raloxifene and its glucuronide (3, and 6’) metabolites. Subsequently Sannova has developed and validated methods for many challenging drugs and their metabolites, including the bisphosphonate Risedronate, both cis and trans Phytonadione, Leuprolide, Mesalamine, Cyclosporin, Disulfiram, Levothyroxine, Tacrolimus, Bupropion, Acetretin, Rivastigmine and many others.
Beginning with a single API 4000 at the time of the company’s founding, Sannova has grown to an organization with 14 triple quad LC/MS/MS systems, including two API 6500 systems, seven API 5500 systems, two API 5000 systems, and 3 API 4000 systems, including one QTrap.
For inorganic analytes, Sannova offers the advanced Agilent 7900 ICP-MS, equipped with a collision cell to minimize isotopic interferences. We have successfully developed methods for the bioanalysis viz; free and transferrin bound iron for administered iron complexes and for biomarkers such as pyrophosphate.
We are particularly pleased when our efforts have inspired our clients to tell us that we have set a new bar, whether it be with our success at turnaround times in first to file settings, or whether it be with our signature “Z factor” approach to analytical methods. The latter has been key to our client’s high rate of success for NDA and ANDA filings.
Sannova will be pleased to meet with you to discuss how our high standards can be a key factor in your success.